Table 1.
Baseline characteristics of the included studies
| Author | Year | Study type | Device | Months of follow-up | Patients | Female (%) | Age (± SD) | CAD (%) | HT (%) | DM (%) | AF (%) | NYHA class III (%) | Mean EF (± SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malek et al | 2015 | Prospective non-randomized | IASD, DC Devices | 12.00 | 11.00 | 55.00 | 70.00 (± 11.90) | 36.00 | 91.00 | 45.00 | 36.00 | 81.80 | 57.00 (± 9.00) |
| Del Trigo et al | 2016 | Prospective non-randomized | V-Wave, first gen | 3.00 | 9.00 | 10.00 | 62.00 (± 8.00) | 90.00 | 70.00 | 70.00 | 70.00 | 100.00 | 24.50 (± 8.30) |
| REDUCE LAP-HF | 2016 | Prospective non-randomized | IASD II, Corvia Medical | 6.00 | 64.00 | 34.37 | 69.00 (± 8.00) | 23.00 | 81.00 | 34.00 | 61.00 | 73.00 | 47.00 (± 7.00) |
| REDUCE LAP-HF I | 2018 | RCT | IASD II, Corvia Medical | 12.00 | 22.00 | 36.00 | 69.60 (± 8.30) | 47.60 | 81.80 | 54.50 | 54.50 | 100.00 | 59.90 (± 9.00) |
| Rodes-Cabau | 2018 | Prospective non-randomized | V-Wave, first gen | 27.00 | 38.00 | 8.00 | 66.00 (± 9.00) | 79.00 | 84.00 | 68.00 | 53.00 | 97.00 | 50.00 (± 9.00) |
| Guimares | 2020 | Prospective non-randomized | V,Wave, second gen | 12.00 | 6.00 | 20.00 | 68.00 (± 9.00) | 80.00 | 70.00 | 50.00 | 60.00 | 100.00 | 34.00 (± 12.00) |
| Simar et al | 2020 | Prospective non-randomized | LA-to-CS | 7.00 | 8.00 | 18.00 | 79.66 (± 4.02) | 62.50 | 75.00 | 0.00 | 87.50 | 87.50 | 53.15 (± 4.00) |
| PRELIEVE study | 2021 | Prospective non-randomized | AFR, Occlutech | 12.00 | 53.00 | 41.00 | 68.20 (± 8.80) | 72.00 | 49.00 | 49.00 | 93.00 | ||
| RAISE trial | 2022 | Prospective non-randomized | NoYa system | 6.00 | 10.00 | 60.00 | 60.10 (± 14.70) | 0.00 | 40.00 | 30.00 | 20.00 | 40.00 | 62.82 (± 2.40) |
| REDUCE LAP-HF II | 2022 | RCT | IASD II, Corvia Medical | 12.00 | 309.00 | 64.00 | 72.30 (± 7.44) | 26.00 | 89.00 | 37.00 | 50.00 | 77.00 | 60.00 (± 7.44) |
| Shang et al | 2022 | Prospective non-randomized | D-shant | 6.00 | 6.00 | 50.00 | 57.83 (± 12.66) | 33.00 | 66.00 | 0.00 | 50.00 | 27.60 (± 13.13) |
AF atrial fibrillation, BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, EF ejection fraction, HT hypertension, NYHA New-York heart association, RCT randomized controlled trial